Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.
Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a"boxed" warn...
Main Authors: | Ryan E Feaver, M Scott Bowers, Banumathi K Cole, Steve Hoang, Mark J Lawson, Justin Taylor, Brian D LaMoreaux, Lin Zhao, Brad R Henke, Brian A Johns, Andrew C Nyborg, Brian R Wamhoff, Robert A Figler |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0291330&type=printable |
Similar Items
-
Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome
by: Masanari Kuwabara, et al.
Published: (2024-01-01) -
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
by: Markus Bredemeier, et al.
Published: (2018-02-01) -
Xanthine Oxidase—A Personal History
by: Russ Hille
Published: (2023-02-01) -
Xanthine oxidase inhibitors in asymptomatic hyperuricemia
by: O. V. Zhelyabina, et al.
Published: (2019-10-01) -
Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats
by: Yoshitaka Tayama, et al.
Published: (2022-12-01)